Grant: Master's Award: Canada Graduate Scholarships
Université Laval
$27,000.00
Identification of genetic signatures of the JAG1 gene in the NOTCH signaling pathway as a candidate modifier of the age of onset of primary open-angle glaucoma at the glaucoma modifier locus 2 (MOG2) on chromosome 20.
EF 2024-25
Résumé
Glaucoma is the leading cause of blindness in people over the age of 50. This disease is often associated with intraocular hypertension (IOP) and is characterized by damage to the optic nerve and loss of visual fields. Glaucoma is also a genetic disease; in Quebec, more than 25% of patients belong to families where the disease is inherited in an autosomal dominant (AD) manner.Our laboratory studies two large French-Canadian families, the CA and BV families, where mutations in the MYOC or FOXC1 genes respectively cause AD glaucoma with onset ages ranging from 2 to 80 years. This variability is surprising because all patients carry the same mutation. We hypothesized that modifier genes interact with the causal mutations. We selected the JAG1 gene as a candidate because it is part of the NOTCH pathway. This pathway could alter the signaling between the diseased cells of the trabeculum. The trabeculum filters the aqueous humor from the eye into the extraocular lymphatic network and the cells that make it up maintain intraocular pressure homeostasis. Primary mutations alter the function of the trabeculum causing IOP. We hypothesize that increased expression of JAG1 stimulate NOTCH to counteract the deleterious effects of primary mutations.My objective is to determine if DNA signatures of JAG1 are associated with variability in the ages of onset. I am sequencing JAG1 in 184 members of the two families. To date, I have identified 6 enhancer regions that amplify the transcriptional levels of JAG1 mRNAs. DNA variations in these enhancers would alter the levels of JAG1 mRNAs, which would then modify the patients' responses to MYOC and FOXC1 mutations. A better understanding of JAG1 will allow us to target individuals at risk for glaucoma in order to offer precision medicine.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
529945
Name
Morneau-Cartier Philippe
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of genetic signatures of the JAG1 gene in the NOTCH signaling pathway as a candidate modifier of the age of onset of primary open-angle glaucoma at the glaucoma modifier locus 2 (MOG2) on chromosome 20.
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antagonistic Pleiotropy; Enhancer; Epistasis; Genetic; Glaucoma; Modifier; Ophtalmology; Pedigree; Sequencing; Signaling Pathways
Abstract
Glaucoma is the leading cause of blindness in people over the age of 50. This disease is often associated with intraocular hypertension (IOP) and is characterized by damage to the optic nerve and loss of visual fields. Glaucoma is also a genetic disease; in Quebec, more than 25% of patients belong to families where the disease is inherited in an autosomal dominant (AD) manner.Our laboratory studies two large French-Canadian families, the CA and BV families, where mutations in the MYOC or FOXC1 genes respectively cause AD glaucoma with onset ages ranging from 2 to 80 years. This variability is surprising because all patients carry the same mutation. We hypothesized that modifier genes interact with the causal mutations. We selected the JAG1 gene as a candidate because it is part of the NOTCH pathway. This pathway could alter the signaling between the diseased cells of the trabeculum. The trabeculum filters the aqueous humor from the eye into the extraocular lymphatic network and the cells that make it up maintain intraocular pressure homeostasis. Primary mutations alter the function of the trabeculum causing IOP. We hypothesize that increased expression of JAG1 stimulate NOTCH to counteract the deleterious effects of primary mutations.My objective is to determine if DNA signatures of JAG1 are associated with variability in the ages of onset. I am sequencing JAG1 in 184 members of the two families. To date, I have identified 6 enhancer regions that amplify the transcriptional levels of JAG1 mRNAs. DNA variations in these enhancers would alter the levels of JAG1 mRNAs, which would then modify the patients' responses to MYOC and FOXC1 mutations. A better understanding of JAG1 will allow us to target individuals at risk for glaucoma in order to offer precision medicine.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Morneau-Cartier, Philippe
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~